ethyl 5-chloro-6-ethyl-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxylate | 862122-52-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: ethyl 5-chloro-6-ethyl-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxylate
• 英文别名: ethyl 5-chloro-6-ethyl-2-oxo-1-propan-2-ylpyridine-3-carboxylate
• CAS: 862122-52-9
• 化学式: C₁₃H₁₈ClNO₃
• 分子量: 271.744
• InChiKey: NYAXBGPQRPQGBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 5-chloro-6-ethyl-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxylate 、 Ethyl 5-Chloro-1-Isopropyl-6-Methyl-2-oxo-1,2-Dihydropyridine-3-Carboxylate 生成 5-chloro-6-ethyl-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid
  参考文献：
  名称：

  1-Isopropyl-2-Oxo-1,2-dihydropyridine-3-carboxamide Derivatives having 5-HT4 Receptor Agonistic Activity

  摘要：

  本发明提供了一种化合物，其化学式为(I)：其中，R1代表具有1至4个碳原子的烷基或卤素原子，R2代表具有1至4个碳原子的烷基，R3代表氢原子或羟基，A代表氧原子或式为—C(R4)(R5)—的基团（其中，R4代表氢原子或具有1至4个碳原子的烷基，R5代表羟基或具有1至4个碳原子的烷氧基），或其药学上可接受的盐。这些化合物具有5-HT4受体激动活性，因此对哺乳动物，尤其是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等疾病的治疗具有用处。

  公开号：

  US20100144789A1

文献信息

• [EN] 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY<br/>[FR] DERIVES DE 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE PRESENTANT UNE ACTIVITE AGONISTE DU RECEPTEUR5-HT4
  申请人：PFIZER JAPAN INC

  公开号：WO2005073222A1

  公开（公告）日：2005-08-11

  This invention provides a compound of formula (I): wherein R1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R2 represents an alkyl group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or a hydroxy group, and A represents an oxygen atom or a group of the formula -C(R4)(R5)- (in which R4 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms and R5 represents a hydroxy group or an alkoxy group having from 1 to 4 carbon atoms) or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

  该发明提供了一个化合物，其化学式为(I)：其中R1代表具有1到4个碳原子的烷基基团或卤素原子，R2代表具有1到4个碳原子的烷基基团，R3代表氢原子或羟基团，A代表氧原子或具有化学式-C(R4)(R5)-的基团（其中R4代表氢原子或具有1到4个碳原子的烷基基团，R5代表羟基或具有1到4个碳原子的烷氧基）或其药用可接受的盐。这些化合物具有5-HT4受体激动活性，因此对于治疗哺乳动物，尤其是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等疾病是有用的。
• 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity
  申请人：Kato Tomoki

  公开号：US20080293767A1

  公开（公告）日：2008-11-27

  This invention provides a compound of formula (I): wherein R 1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R 2 represents an alkyl group having from 1 to 4 carbon atoms, R 3 represents a hydrogen atom or a hydroxy group, and A represents an oxygen atom or a group of the formula —C(R 4 )(R 5 )— (in which R 4 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms and R 5 represents a hydroxy group or an alkoxy group having from 1 to 4 carbon atoms) or a pharmaceutically acceptable salts thereof. These compounds have 5-HT 4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

  本发明提供了一种式（I）的化合物：其中R1代表具有1至4个碳原子的烷基或卤素原子，R2代表具有1至4个碳原子的烷基，R3代表氢原子或羟基，A代表氧原子或式—C（R4）（R5）—的基团（其中R4代表氢原子或具有1至4个碳原子的烷基，R5代表羟基或具有1至4个碳原子的烷氧基），或其药学上可接受的盐。这些化合物具有5-HT4受体激动活性，因此对于哺乳动物，特别是人类的治疗胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等非常有用。
• 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity
  申请人：Kato Tomoki

  公开号：US08362038B2

  公开（公告）日：2013-01-29

  This invention provides a compound of formula (I): wherein R1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R2 represents an alkyl group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or a hydroxy group, and A represents an oxygen atom or a group of the formula —C(R4)(R5)— (in which R4 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms and R5 represents a hydroxy group or an alkoxy group having from 1 to 4 carbon atoms) or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

  本发明提供了化合物(I)的结构式，其中R1代表具有1至4个碳原子的烷基或卤素原子，R2代表具有1至4个碳原子的烷基，R3代表氢原子或羟基，A代表氧原子或公式-C(R4)(R5)-的基团（其中R4代表氢原子或具有1至4个碳原子的烷基，R5代表羟基或具有1至4个碳原子的烷氧基），或其药学上可接受的盐。这些化合物具有5-HT4受体激动活性，因此对于哺乳动物，特别是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等治疗非常有用。
• 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT sb 4 /sb RECEPTOR AGONISTIC ACTIVITY
  申请人：Pfizer, Inc.

  公开号：EP1713797A1

  公开（公告）日：2006-10-25
• 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY
  申请人：Pfizer, Inc.

  公开号：EP1713797B1

  公开（公告）日：2008-03-05